Pharmaceutical

GSK’s lung cancer therapy gains EMA PRIME designation

GSK’s GSK’227 has gained Priority Medicines (PRIME) designation from the EMA for the treatment of relapsed ES-SCLC.

Dec 17, 2024 - 06:00
GSK’s lung cancer therapy gains EMA PRIME designation
GSK’s GSK’227 has gained Priority Medicines (PRIME) designation from the EMA for the treatment of relapsed ES-SCLC.
Read the original article

Tags:

Previous Article

CTO Europe 2024: keep the burden of trials away from patients, say experts

Next Article

ADCs breach barriers to become mainstream cancer treatment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Sophisticated phishing and deepfakes: How generative AI brings new threats for hospitals

STAT+: Sophisticated phishing and deepfakes: How genera...

Jan 30, 2024

The science of viscous drug product filling: Pumps, pressure, and process optimization

The science of viscous drug product filling: Pumps, pre...

Oct 16, 2024

She got off dialysis. Her doctor thinks others with acute kidney injury can too

She got off dialysis. Her doctor thinks others with acu...

Sep 28, 2023